Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Dermata Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 8 | +8 |
| Shares | 0 | 264.0K | +264.0K |
| Value | $0 | $1.19M | +$1.19M |
New holders (8)
Institutions that held Dermata Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AIGH Capital Management LLC | 175,000 | $786.0K | 0.23% |
| Worth Venture Partners, LLC | 40,075 | $180.0K | 0.08% |
| Virtu Financial LLC | 22,496 | $101.0K | 0.01% |
| Geode Capital Management, LLC | 15,860 | $71.0K | 0.00% |
| BlackRock Inc. | 5,751 | $26.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 4,576 | $21.0K | 0.00% |
| UBS Group AG | 189 | $1.00K | 0.00% |
| Wells Fargo & Company | 16 | $0 | 0.00% |
Sold out (0)
Institutions that held Dermata Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.